证券代码：688382 证券简称：益方生物 公告编号：2025-050 益方生物科技（上海）股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、会议召开和出席情况 1、 公司在任董事9人，列席9人； 2、 公司董事会秘书出席本次会议；其他高级管理人员列席本次会议。 二、议案审议情况 （一）非累积投票议案 （一）股东会召开的时间：2025 年 12 月 25 日 （二）股东会召开的地点：上海市浦东新区张衡路 1000 弄 63 号 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 309 | | --- | --- | | 普通股股东人数 | 309 | | 2、出席会议的股东所持有的表决权数量 | 270,778,965 | | 普通股股东所持有表决权数量 | 270,778,965 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 ...

上海石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 君合律师事务所上海分所 关于益方生物科技（上海）股份有限公司 2025 年第二次临时股东会的法律意见书 致：益方生物科技（上海）股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受益方生物科技（上海） 股份有限公司（以下简称"公司"）的委托，指派本所律师列席了公司于 2025 年 12 月 25 日在上海市浦东新区张衡路 1000 弄 63 号召开的 2025 年第二次临时 股东会（以下简称"本次股东会"）的现场会议。现本所根据《中华人民共和国 公司法》（以下简称"《公司法》"）《中华人民共和国证券法》《上市公司股 东会规则》（以下简称"《股东会规则》"）等中国现行法律、法规和规范性文 件以及《益方生物科技（上海）股份有限公司章程》（以下简称"《公司章程》"） 《益方生物科技（上海）股份有限公司股东会议事规则》的有关规定，就本次股 东会有关事宜出具法律意见书。 本法律意见书仅就本次股东会的召集和召开程序是 ...

Core Viewpoint - The A-share commercial aerospace sector experienced a significant surge, with the Satellite ETF (159206) rising over 6%, leading the market [3] Group 1: Market Performance - The Satellite ETF reached a new high in scale at 4.159 billion yuan [4] - Notable stocks included Chaojie Co. (301005) with a 20% increase, and several others like Shanghai Port (605598) and Shenglu Communication (002446) achieving 10% increases [4] - The Satellite ETF has seen continuous net inflows over the past nine days, totaling 1.418 billion yuan, with a peak single-day inflow of 353 million yuan [5] Group 2: Industry Developments - As of December 23, 2025, China conducted nearly 90 space launches, setting a historical record, with 23 of these by private commercial rocket companies [7] - The China Manned Space Engineering Office announced plans for four missions in 2026, including the first launch of the Long March 10A reusable rocket [7] - According to a report by China International Capital Corporation, the satellite industry is at a critical turning point, with expectations for significant growth in satellite tenders and launch volumes [7] Group 3: Investment Opportunities - The Satellite ETF focuses on commercial aerospace and satellite communication, positioned to benefit from China's ambitions as a "space power" [8] - The ETF is the first of its kind in the market, established on March 6, 2025, and is expected to see accelerated growth due to supportive policies and decreasing launch costs [8]

Core Viewpoint - Yifang Bio experienced a stock price decline of 2.07% on December 23, with a current price of 29.38 CNY per share and a total market capitalization of 16.992 billion CNY [1] Group 1: Stock Performance - Yifang Bio's stock has increased by 120.90% year-to-date, with a slight increase of 0.44% over the last five trading days and an 8.41% increase over the last 20 days, but a decline of 12.84% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on October 31, where it recorded a net buy of -392.836 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Yifang Bio reported a revenue of 30.8935 million CNY, representing a year-on-year growth of 61.27%, while the net profit attributable to shareholders was -181 million CNY, showing a year-on-year increase of 40.59% [2] - As of September 30, 2025, the number of shareholders increased by 26.17% to 12,400, while the average circulating shares per person decreased by 17.52% to 33,810 shares [2] Group 3: Shareholder Structure - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 16.2161 million shares, an increase of 8.162 million shares compared to the previous period [2] - New entrants among the top ten circulating shareholders include Ping An Medical Health Mixed A and Yongying Medical Innovation Selected Mixed Initiation A, holding 6.2749 million shares and 7.9219 million shares, respectively [2]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is opening up long-term value for companies, with significant collaborations occurring since September 2025. The innovative drug index has decreased by 11.34% from September 1 to December 19, underperforming the CSI 300 index by 12.93 percentage points. However, the index has increased by 38.65% since the beginning of the year, outperforming the CSI 300 index by 20.76 percentage points [2] - The report emphasizes the importance of oral immunomodulatory drugs, highlighting the positive results from Takeda's TYK2 inhibitor, zasocitinib, in treating moderate to severe plaque psoriasis. This drug is expected to provide significant benefits to patients and is part of a broader trend of domestic companies developing oral immunomodulatory drugs [3] - The report notes the progress of domestic small nucleic acid drugs, with YKYY032 receiving clinical approval from both the FDA and NMPA. The report anticipates an increase in clinical approvals for small nucleic acid drugs by 2026, as more companies enter this field [5] - The report tracks the flu season, indicating a peak in flu cases and a corresponding increase in the use of new flu medications, which are expected to see significant sales growth due to improved treatment protocols and online sales [7] - The report highlights a recovery in the financing of domestic innovative drugs, with a total financing amount of $5.51 billion in the first three quarters of 2025, a 67.6% increase year-on-year. The report also notes a significant increase in orders for CXO companies, indicating a positive trend in the industry [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.14 percentage points in the last week, ranking 22nd among 31 sectors [20] - Over the past month, the pharmaceutical industry underperformed the CSI 300 index by 2.06 percentage points, ranking 19th [24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has decreased by 2.50% over the past month, underperforming the CSI 300 index by 2.06 percentage points [40] - The current PE (TTM) for the pharmaceutical industry index is 37.07, above the five-year historical average of 31.16 [44] 3. Recent Research Achievements - The report includes various deep-dive studies on the pharmaceutical industry, focusing on topics such as the growth of oral drugs and the stability of blood products [48] 4. Recent Industry Policies and News - Recent policies from the National Healthcare Security Administration aim to improve the quality and efficiency of medical insurance fund settlements, which could positively impact the pharmaceutical sector [50] - Significant news includes the approval of new drugs by various companies, indicating ongoing innovation and development within the industry [51][52]

Core Viewpoint - Yifang Bio has shown significant stock performance with a year-to-date increase of 126.24%, despite a recent decline over the past 60 days [1] Group 1: Stock Performance - As of December 22, Yifang Bio's stock price reached 30.09 CNY per share, with a trading volume of 1.25 billion CNY and a market capitalization of 17.403 billion CNY [1] - The stock has experienced a 3.76% increase over the last five trading days and a 13.89% increase over the last 20 trading days, while it has declined by 11.32% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on October 31, where it recorded a net buy of -39.2836 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Yifang Bio reported a revenue of 30.8935 million CNY, reflecting a year-on-year growth of 61.27% [2] - The company recorded a net profit attributable to shareholders of -181 million CNY, which is a 40.59% increase compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, Yifang Bio had 12,400 shareholders, an increase of 26.17% from the previous period, with an average of 33,810 circulating shares per shareholder, down by 17.52% [2] - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 16.2161 million shares, an increase of 8.162 million shares from the previous period [2] - New entrants among the top ten circulating shareholders include Ping An Medical Health Mixed A and Yongying Medical Innovation Selected Mixed Initiated A [2]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The oral treatment landscape for psoriasis has established a dual leadership pattern with TYK2 and IL23 inhibitors, highlighting the potential of companies like Yifang Biopharma, Nocankang, and Haishike [1][16] - The A-share pharmaceutical index has shown a year-to-date increase of 14.49%, while the Hang Seng Healthcare Index has surged by 65.28% [4][9] - The report emphasizes the importance of innovative drugs, with a ranking of preferred sub-industries: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10][12] Industry Trends - The report notes that the A-share pharmaceutical index has underperformed relative to the CSI 300 index, with a slight decrease of 0.14% this week [4][9] - The report highlights the strong performance of the medical commercial sector (+4.94%) and medical devices (+1.16%) this week, while the chemical pharmaceuticals sector saw a decline of -1.74% [4][9] - The report identifies key companies to watch in the TYK2 space, including Yifang Biopharma and Nocankang, as well as those involved in oral IL23 treatments like Haishike [16][12] Company-Specific Recommendations - Recommended companies in the innovative drug sector include: - Yifang Biopharma - Nocankang - Haishike - Heng Rui Medicine - Bai Jie Shen Zhou - Shi Yao Group - Zai Jian Medicine - Di Zhe Medicine [12][16] - In the CXO and research services sector, recommended companies include: - WuXi AppTec - Hao Yuan Medicine - Aopumai - Kingsray Biotech [12] - For traditional Chinese medicine, companies to focus on include: - Zuo Li Pharmaceutical - Fang Sheng Pharmaceutical - Dong E E Jiao [12] Market Performance - The report indicates that the A-share pharmaceutical index has shown a year-to-date increase of 14.49%, while the Hang Seng Healthcare Index has increased by 65.28% [4][9] - The report also notes that the medical commercial sector has performed well this week, with a gain of 4.94% [4][9]

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies involved in the development of oral SERDs for breast cancer treatment. Core Insights - The report highlights the recent FDA approval of Imlunestrant, an oral SERD developed by Eli Lilly, for the treatment of ER+/HER2–/ESR1 mutant advanced or metastatic breast cancer, marking it as the second oral SERD approved after Elacestrant [18][19] - The EMBER-3 trial results indicate that Imlunestrant significantly improves progression-free survival (PFS) compared to standard endocrine therapy, with a median PFS of 5.5 months versus 3.8 months for standard therapy [23] - Giredestrant, developed by Roche, has shown positive results in the III phase evERA trial, demonstrating significant benefits in PFS compared to standard treatment in patients previously treated with CDK4/6 inhibitors [27] - Camizestrant, another oral SERD from AstraZeneca, has shown promising efficacy in the SERENA-6 trial, with a median PFS of 16.6 months when combined with CDK4/6 inhibitors [33] Summary by Sections Section 1: Focus on Innovative Drugs - The report reviews the advancements in innovative drugs, particularly in the field of breast cancer treatment, emphasizing the importance of oral SERDs [2][5] Section 2: Current Status of ER+ Breast Cancer Therapies - The report discusses the current landscape of therapies for ER+ breast cancer, including the mechanisms of action for various anti-estrogen therapies and the challenges of resistance faced by patients [10][8] Section 3: Clinical Development of New Oral SERDs - The report details the clinical development progress of several new oral SERDs, including Imlunestrant, Giredestrant, and Camizestrant, highlighting their respective phases and trial outcomes [12][11][33] Section 4: Market Dynamics and Company Performance - The report provides insights into the market dynamics of the biotech sector, including stock performance of key companies involved in the development of innovative cancer therapies [46][49]

Investment Rating - The report maintains an investment rating of "Outperform" with a target of A [7] Core Insights - The report highlights the positive results from Takeda's new generation oral TYK2 inhibitor, zasocitinib (TAK-279), for treating moderate to severe plaque psoriasis, with over 50% of participants achieving skin clearance or nearly clear skin (PASI 90) at week 16, and about 30% achieving complete clearance (PASI 100) [3][4] - The report suggests that there are multiple catalysts expected in the sector, including academic conferences and data readouts, which could provide investment opportunities [2] - The report emphasizes the potential of other TYK2 inhibitors, particularly Eifang Biopharma's D-2570, which has shown promising phase 2 clinical data [4][22] Summary by Sections Weekly New Drug Market Review - From December 15 to December 21, 2025, the top five gainers in the new drug sector were: Yahu Medicine (+12.03%), Cloudtop New Medicine (+9.32%), Aidi Pharmaceutical (+9.06%), Shiyao Group (+7.05%), and Ailis (+3.94%). The top five losers were: Chuangsheng Group (-16.03%), Beihai Kangcheng (-12.33%), Kedi (-11.88%), WuXi AppTec (-11.15%), and Nuocheng Jianhua (-10.99%) [1][17] Weekly Focus on Recommended Stocks - The report recommends focusing on companies with high certainty for overseas expansion, such as Sanofi Biopharma, Lianbang Pharmaceutical, and Kelun Biotech. It also highlights companies with potential overseas data catalysts, including Betta Pharmaceuticals, Hutchison China MediTech, and Ying'en Biopharma [2][21] Weekly New Drug Industry Analysis - Takeda's phase 3 clinical trials for zasocitinib have shown consistent results with previous phase 2 trials, indicating strong data reliability. The report also notes the potential for TYK2 inhibitors in treating Crohn's disease and ulcerative colitis [3][4][22] Weekly New Drug Application Approval & Acceptance - No new drug or new indication applications were approved domestically this week, but 11 new drug or new indication applications were accepted [5][26] Weekly New Drug Clinical Application Approval & Acceptance - This week, 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [11][28]

本次授予为一次性授予，无预留权益。激励计划涉及的激励对象共计179人，授予价格为16.87元/股。 12月19日，益方生物(688382.SH)披露2025年限制性股票激励计划(草案)，拟授予激励对象的限制性股票 数量为557.7万股，约占激励计划草案公布日公司股本总额的0.96%。 ...